A Study Evaluating 10 mg and 25 mg Doses of Etanercept in Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the safety and efficacy for two regimens of etanercept in patients with rheumatoid arthritis (RA). The two regimens to be compared are a 25mg twice weekly regimen and a 50mg once weekly regimen.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Presence of >6 swollen joints and >6 tender joints

• Inadequate response to at least one disease modifying anti-rheumatic drug (DMARD)

• Have not been treated with a DMARD for at least 4 weeks prior to the baseline visit

Exclusion Criteria:

• Previous treatment with etanercept, antibody to TNFα, or other TNFα inhibitors

• Received investigational drugs within 6 months of the baseline visit

• Received intra-articular hyaluronic acid injections within 4 weeks of the baseline visit